Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency.

Sokol H, Mahlaoui N, Aguilar C, Bach P, Join-Lambert O, Garraffo A, Seksik P, Danion F, Jegou S, Straube M, Lenoir C, Neven B, Moshous D, Blanche S, Pigneur B, Goulet O, Ruemmele F, Suarez F, Beaugerie L, Pannier S, Mazingue F, Lortholary O, Galicier L, Picard C, de Saint Basile G, Latour S, Fischer A.

J Allergy Clin Immunol. 2019 Feb;143(2):775-778.e6. doi: 10.1016/j.jaci.2018.09.021. Epub 2018 Oct 10. No abstract available.

PMID:
30312711
2.

Nutrition, oxidative stress and intestinal dysbiosis: Influence of diet on gut microbiota in inflammatory bowel diseases.

Tomasello G, Mazzola M, Leone A, Sinagra E, Zummo G, Farina F, Damiani P, Cappello F, Gerges Geagea A, Jurjus A, Bou Assi T, Messina M, Carini F.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Dec;160(4):461-466. doi: 10.5507/bp.2016.052. Epub 2016 Oct 26. Review.

3.

Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.

Tomasello G, Tralongo P, Damiani P, Sinagra E, Di Trapani B, Zeenny MN, Hussein IH, Jurjus A, Leone A.

World J Gastroenterol. 2014 Dec 28;20(48):18121-30. doi: 10.3748/wjg.v20.i48.18121. Review.

4.

Intestinal dysbiosis in inflammatory bowel disease.

Kaur N, Chen CC, Luther J, Kao JY.

Gut Microbes. 2011 Jul-Aug;2(4):211-6. doi: 10.4161/gmic.2.4.17863. Epub 2011 Jul 1. Review.

PMID:
21983063
5.

Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis.

Ray A, Dittel BN.

Immunology. 2015 Nov;146(3):359-68. doi: 10.1111/imm.12511. Epub 2015 Sep 7. Review.

6.

Dysbiosis in gastrointestinal disorders.

Chang C, Lin H.

Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):3-15. doi: 10.1016/j.bpg.2016.02.001. Epub 2016 Feb 16. Review.

PMID:
27048892
7.

Intestinal dysbiosis in children with short bowel syndrome is associated with impaired outcome.

Engstrand Lilja H, Wefer H, Nyström N, Finkel Y, Engstrand L.

Microbiome. 2015 May 4;3:18. doi: 10.1186/s40168-015-0084-7. eCollection 2015.

8.

Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot?

Shapiro JM, Cho JH, Sands BE, LeLeiko NS.

Clin Gastroenterol Hepatol. 2015 May;13(5):842-6. doi: 10.1016/j.cgh.2015.02.028. Epub 2015 Feb 25. Review.

PMID:
25725444
9.

Increased Expression of DUOX2 Is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine.

Grasberger H, Gao J, Nagao-Kitamoto H, Kitamoto S, Zhang M, Kamada N, Eaton KA, El-Zaatari M, Shreiner AB, Merchant JL, Owyang C, Kao JY.

Gastroenterology. 2015 Dec;149(7):1849-59. doi: 10.1053/j.gastro.2015.07.062. Epub 2015 Aug 7.

10.

Mechanisms and consequences of intestinal dysbiosis.

Weiss GA, Hennet T.

Cell Mol Life Sci. 2017 Aug;74(16):2959-2977. doi: 10.1007/s00018-017-2509-x. Epub 2017 Mar 28. Review.

11.

Dysbiosis, inflammation, and response to treatment: a longitudinal study of pediatric subjects with newly diagnosed inflammatory bowel disease.

Shaw KA, Bertha M, Hofmekler T, Chopra P, Vatanen T, Srivatsa A, Prince J, Kumar A, Sauer C, Zwick ME, Satten GA, Kostic AD, Mulle JG, Xavier RJ, Kugathasan S.

Genome Med. 2016 Jul 13;8(1):75. doi: 10.1186/s13073-016-0331-y.

12.
13.

Dysbiosis in intestinal inflammation: Cause or consequence.

Buttó LF, Haller D.

Int J Med Microbiol. 2016 Aug;306(5):302-309. doi: 10.1016/j.ijmm.2016.02.010. Epub 2016 Mar 4. Review.

PMID:
27012594
14.

PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.

Spalinger MR, Kasper S, Chassard C, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, Scharl M.

Mucosal Immunol. 2015 Jul;8(4):918-29. doi: 10.1038/mi.2014.122. Epub 2014 Dec 10.

PMID:
25492475
15.

Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.

Eom T, Kim YS, Choi CH, Sadowsky MJ, Unno T.

J Microbiol. 2018 Mar;56(3):189-198. doi: 10.1007/s12275-018-8049-8. Epub 2018 Feb 28. Review.

PMID:
29492876
16.

Perturbed Mucosal Immunity and Dysbiosis Accompany Clinical Disease in a Rat Model of Spondyloarthritis.

Asquith MJ, Stauffer P, Davin S, Mitchell C, Lin P, Rosenbaum JT.

Arthritis Rheumatol. 2016 Sep;68(9):2151-62. doi: 10.1002/art.39681.

17.

Severe intestinal dysbiosis is prevalent in primary Sjögren's syndrome and is associated with systemic disease activity.

Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K.

Arthritis Res Ther. 2017 Oct 24;19(1):237. doi: 10.1186/s13075-017-1446-2.

18.

Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice.

Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, Vilchez-Vargas R, Vital M, Pieper DH, Vanden Bussche J, Vanhaecke L, Van de Wiele T, De Vos M, Laukens D.

Appl Environ Microbiol. 2017 Mar 17;83(7). pii: e02766-16. doi: 10.1128/AEM.02766-16. Print 2017 Apr 1.

19.

The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease?

Bien J, Palagani V, Bozko P.

Therap Adv Gastroenterol. 2013 Jan;6(1):53-68. doi: 10.1177/1756283X12454590.

20.

Intestinal barrier in inflammatory bowel disease.

Antoni L, Nuding S, Wehkamp J, Stange EF.

World J Gastroenterol. 2014 Feb 7;20(5):1165-79. doi: 10.3748/wjg.v20.i5.1165. Review.

Supplemental Content

Support Center